The Journals of Gerontology paper from the Women's Interagency HIV Study cohort, published May 4 and confirmed Friday by the NYU Rory Meyers group, reports that a monocyte-specific epigenetic clock tracks non-somatic depressive symptoms — anhedonia, hopelessness, and feelings of failure — more sharply than the physical symptoms of depression in a 440-woman validation cohort with and without HIV. [1] The discrimination matters because cognitive-affective and somatic depression historically respond to different treatment classes; SSRIs have been more effective for the latter than the former.

The Sunday brief framed the validation step as the move from cross-sectional observation to prospective testing in a broader population. The Day-after clinical reading is sharper. The monocyte-clock's discriminating signal sits on the cognitive-affective side of the depression phenotype, the side the rodent literature has indexed for a decade without a translatable assay. The 440-woman cohort delivers the first human cross-section in which the assay holds. [2] The hypothesis under index is that chronic peripheral inflammation drives both the accelerated monocyte aging and the cognitive depression symptoms; the clock tests the signal, not the mechanism.

The translation question is treatment selection. If anhedonia and hopelessness map onto an inflammatory monocyte-clock signature distinct from somatic depression, the clinician's first choice may shift from SSRI to anti-inflammatory adjunct in a population the rating scales have always lumped together. [3] The biomarker also opens a discriminating endpoint for the late-phase anti-inflammatory antidepressant programs that have, to date, failed on undifferentiated depression endpoints.

The validation cohort holds. The clinical-translation question is whose lab takes it next.

-- KENJI NAKAMURA, Tokyo